X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-october-25-2023-66768.pdf
https://www.onclive.com/view/ibrutinib-plus-chemoimmunotherapy-fails-to-improve-pfs-in-pretreated-follicular-lymphoma-mzl
https://www.globenewswire.com/news-release/2023/06/07/2683755/0/en/LIXTE-Biotechnology-and-the-Spanish-Sarcoma-Group-Enroll-First-Patient-in-a-Phase-1b-2-Randomized-Trial-of-Doxorubicin-LIXTE-s-Lead-Anti-Cancer-Compound-LB-100-in-Advanced-Soft-Tis.html
https://endpts.com/fda-adcomm-votes-11-2-to-expand-roches-polivy-label-in-dlbcl/
https://www.ema.europa.eu/en/documents/overview/celdoxome-pegylated-liposomal-epar-medicine-overview_en.pdf
https://www.biospace.com/article/seagen-eyes-a-key-frontline-indication-for-adcetris/
https://www.globenewswire.com/news-release/2022/11/14/2554786/0/en/Apexigen-Announces-Positive-Interim-Results-from-Phase-2-Trial-Evaluating-its-CD40-Antibody-Sotigalimab-in-Combination-with-Doxorubicin-in-Patients-with-Liposarcoma.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212219
https://www.globenewswire.com/news-release/2022/10/13/2533870/0/en/LIXTE-BIOTECHNOLOGY-ANNOUNCES-APPROVAL-OF-A-PHASE-1B-2-RANDOMIZED-TRIAL-OF-DOXORUBICIN-LB-100-IN-ADVANCED-SOFT-TISSUE-SARCOMAS-TO-BE-CONDUCTED-BY-THE-SPANISH-SARCOMA-GROUP.html
https://www.prnewswire.com/news-releases/shasqi-advances-sq3370-to-phase-2-in-solid-tumors-301621697.html
https://www.clinicaltrialsarena.com/news/biocytogen-tracon-sarcoma-trial/
https://www.labiotech.eu/trends-news/genentech-lymphoma-treatment/
https://www.fiercepharma.com/pharma/avactas-doxorubicin-prodrug-clears-another-early-safety-test
https://www.ema.europa.eu/en/medicines/human/EPAR/zolsketil-pegylated-liposomal
https://www.expresspharma.in/european-commission-approves-roches-polivy-combination-for-people-with-previously-untreated-diffuse-large-b-cell-lymphoma/
https://www.globenewswire.com/news-release/2022/01/12/2365620/0/en/ImmixBio-IMX-110-Produced-50-Positive-Response-Rate-in-First-Line-Therapy-Resistant-Cancer-Surpassing-the-Standard-of-Care-in-Mice-Study.html
https://www.cancernetwork.com/view/progression-free-survival-boost-noted-with-polatuzumab-vedotin-plus-r-chp-for-previously-untreated-dlbcl
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207228
https://www.onclive.com/view/lurbinectedin-doxorubicin-misses-os-end-point-in-relapsed-sclc-but-shows-superior-safety-vs-soc
https://www.prnewswire.com/news-releases/oncopeptides-presents-new-clinical-and-preclinical-melflufen-data-at-the-upcoming-european-hematology-association-meeting-301289913.html
https://www.europeanpharmaceuticalreview.com/news/142938/novel-ionic-liquid-enables-uniform-chemotherapy-delivery-in-solid-tumours/
https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-and-pharmamar-announce-results-of-atlantis-phase-3-study-evaluating-zepzelca-in-combination-with-doxorubicin-for-patients-with-small-cell-lung-cancer-following-one-prior-platinum-containing-line-301185390.html
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-december-2-2020-1606885653.pdf
https://www.esmo.org/meetings/esmo-virtual-congress-2020/daily-reporter/daily-reporter-news/increased-clarity-on-role-immunotherapy-early-tnbc
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212299
https://www.protokinetix.com/protokinetix-aagp-moves-to-whole-organ-transplantation-testing/
https://www.takeda.com/newsroom/newsreleases/2020/takeda-receives-positive-chmp-opinion-for-adcetris-brentuximab-vedotin-in-combination-with-chp-cyclophosphamide-doxorubicin-and-prednisone/
https://seekingalpha.com/news/3508477-hexo-closes-c-70m-convertible-debt-deal
https://endpts.com/big-pharma-joins-200m-uk-biobank-sequencing-project-monopar-sets-terms-for-40m-ipo/
https://www.fiercepharma.com/pharma/seattle-genetics-investors-breathe-a-sigh-relief-as-adcetris-scores-30-sales-growth
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206062
https://www.ema.europa.eu/en/news/ema-recommends-withdrawal-marketing-authorisation-cancer-medicine-lartruvo
https://www.businesswire.com/news/home/20190211005381/en/European-Commission-Approves-ADCETRIS%C2%AE-brentuximab-vedotin-AVD
https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2019/68974a-eng.php
https://www.prnewswire.com/news-releases/apexigen-announces-clinical-collaboration-on-a-new-phase-2-trial-for-apx005m-in-sarcoma-300769282.html
https://www.ema.europa.eu/documents/scientific-guideline/pegylated-liposomal-doxorubicin-hydrochloride-concentrate-solution-2-mg/ml-product-specific-bioequivalence-guidance_en.pdf
https://seekingalpha.com/article/4224046-cancer-research-highlight-merck-kgaa-gets-deeper-trouble-immune-checkpoint-inhibition
https://www.prnewswire.com/news-releases/pharmamar-will-present-the-results-of-the-phase-i-ii-study-with-lurbinectedin-in-combination-with-doxorubicin-in-relapsed-small-cell-lung-cancer-during-the-iaslc-world-conference-878447271.html
Market Place
Share 
